SuperworthShoulder Innovations SI
- Market cap
- $409.3M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 6.8×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $60.1M
- +61% on a year ago
- Net margin
- −58.3%
- Free cash flow yield
- −11.5%
Shoulder Innovations trades at 6.8× sales. Its trailing earnings are negative, so it has no PE. Revenue was $60.1M over the last twelve months, up 61% on a year earlier with a −58% net margin.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| $7.2M | $8.3M | $7.5M | $8.7M | $10.1M+41% | $11M+33% | $11.8M+58% | $14.4M+65% | $16.7M+65% | $17.2M+56% | |
| Cost of revenue | $1.7M | $1.9M | $1.8M | $2M | $2.3M+41% | $2.6M+38% | $2.8M+59% | $3.4M+72% | $3.7M+59% | $3.7M+43% |
| Gross profit | $5.5M | $6.4M | $5.7M | $6.8M | $7.8M+41% | $8.4M+32% | $9M+57% | $11.1M+63% | $13M+67% | $13.4M+60% |
| R&D | $1.1M | $1.2M | $1.1M | $1.2M | $1.6M+48% | $1.4M+21% | $1.5M+40% | $3.2M+176% | $3.8M+137% | $3.4M+141% |
| SG&A | $7.7M | $9.2M | $8.5M | $9.1M | $10.5M+36% | $12.8M+40% | $15.1M+78% | $16.3M+79% | $18.2M+73% | $20.1M+56% |
| −$3.3M | −$4M | −$3.9M | −$3.5M | −$4.3M+32% | −$5.9M+47% | −$7.6M+97% | −$8.5M+140% | −$9M+109% | −$10M+71% | |
| Interest expense | $317K | $292K | $316K | $391K | $367K+16% | $216K−26% | $78K−75% | −$591K | −$436K | −$673K |
| Pre-tax income | −$3.6M | −$4.2M | −$4.1M | −$3.8M | −$4.7M+30% | −$19.2M+360% | −$8.7M+115% | −$7.8M+105% | −$8.4M+80% | −$10.2M−47% |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net income | −$3.6M | −$4.2M | −$4.1M | −$3.8M | −$4.7M+30% | −$19.2M+360% | −$8.7M+115% | −$7.8M+105% | −$8.4M+80% | −$10.2M−47% |
| −$62.77 | −$72.74 | −$68.31 | −$45.20 | −$52.13−17% | −$165.53+128% | −$0.64−99% | −$0.38−99% | −$0.41−99% | −$0.49−100% | |
| 57.4K | 57.4K | 59.4K | 83.9K | 89.4K+56% | 116K+102% | 13.6M+22814% | 20.6M+24461% | 20.7M+22992% | 20.7M+17781% |
Revenue: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
R&D: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
SG&A: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Operating income: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Income tax: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Net income: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
EPS, diluted: 4 periods, Q1 FY24 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY24: share-days: the 6-month average less the second quarter's. Q4 FY24 and Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Shoulder Innovations' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SIShoulder Innovations | $409.3M | n/m | n/a | 6.8× | +61% | −58.3% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| Peer median | $552.7M | 22.3× | 24.1× | 2.0× | +4% | 7.8% |
More on Shoulder Innovations
Each number over time
Where it ranks
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .